Recent Quotes (30 days)

You have no recent quotes
chg | %

Takeda Pharmaceutical Co Ltd news

   Watch this stock
Showing stories 1 - 10 of about 129   

Articles published

4502 5,752.00 +57.00 (1.00%)
price chart
Takeda and Nanotherapeutics Announce Agreement to Expand Takeda's ...
ALACHUA, Fla. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (Takeda) (TOKYO: 4502) and Nanotherapeutics, Inc., announced an agreement providing Takeda with expanded commercialization and technology access ...
Takeda Submits New Drug Application for Ixazomib for Patients with Relapsed ...
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that a New Drug Application (NDA) has been submitted to the United States (U.
Takeda submits NDA in the US for ixazomib for the treatment of multiple myeloma  European Pharmaceutical Review
Takeda Announces European Medicines Agency Acceptance of Ixazomib's Marketing ...
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for ixazomib, ...
Takeda Says EMA Accepts MAA For Ixazomib  Nasdaq
Takeda Announces Appointment of New President of U.S. Business Unit
DEERFIELD, Ill., April 13, 2015 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda"), and Takeda's wholly-owned subsidiary, Takeda Pharmaceuticals U.S.
Takeda Announces First Patient Enrolled in Global Phase 3 Study of Ixazomib as ...
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the first patient has been enrolled in the Phase 3 TOURMALINE-MM4 study of investigational oral ixazomib.
Zacks Upgrades Takeda Pharmaceutical Co to Hold (TKPYY)
Takeda Pharmaceutical Co (OTCMKTS:TKPYY) was upgraded by Zacks from a “sell” rating to a “hold” rating in a research report issued on Tuesday, Marketbeat reports.
Takeda Pharmaceutical Co Cut to "Sell" at Zacks (TKPYY)
Takeda Pharmaceutical Co (OTCMKTS:TKPYY) was downgraded by Zacks from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday, MarketBeat.
Takeda, Nanotherapeutics expand agreement for commercialization and technology ...
Takeda Pharmaceutical Company Limited (Takeda), a research-based global company, and Nanotherapeutics, Inc., an integrated biopharmaceutical company, announced an agreement providing Takeda with expanded commercialization and technology ...
Takeda and Nanotherapeutics partner to expand influenza vaccine and other ...  TI News Daily (press release)
Moody's: Takeda's rating not immediately impacted by ACTOS settlement ...
Tokyo, May 01, 2015 -- Moody's Japan K.K. says that the A1 issuer and senior unsecured debt ratings as well as (P)A1 shelf registration of Takeda Pharmaceutical Company Limited ("Takeda") will not be immediately impacted following its 28 April 2015 (U ...
Takeda Pharma drops on $2.7bn charge to settle Actos lawsuits  International Business Times UK
Takeda Pharmaceutical Co Ltd (ADR) Plans To Offer $2.2 Billion To Settle Actos ...
Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) has, as per anonymous sources, expressed its willingness to put down over $2.2 billion in an attempt to settle claims that the company deliberately withheld information about the risk of cancer from ...
Japan's Takeda Pharmaceutical offers $2.2 billion to settle US drug lawsuits  Economic Times
Drugmaker Takeda may settle Actos suits for $2.2 billion  The Japan Times